ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "cytokines"

  • Abstract Number: 1767 • 2013 ACR/ARHP Annual Meeting

    Gender, Race, and Soluble Mediators Distinguish Blood Relatives Who Develop Incomplete Lupus Or Classified SLE In The Lupus Autoimmunity In Relatives (LAUREL) Study

    Melissa E. Munroe1, Kendra A. Young2, Jill M. Norris2, Joel M. Guthridge3, Diane L. Kamen4, Timothy B. Niewold5, Gary S. Gilkeson4, Michael H. Weisman6, Mariko L. Ishimori6, Daniel J. Wallace7, David R. Karp8, John B. Harley9,10 and Judith A. James11,12, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Epidemiology, Colorado School of Public Health, Aurora, CO, 3Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 5Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, 6Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 7Cedars-Sinai Medical Center, Los Angeles, CA, 8Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, 9Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 10US Department of Veterans Affairs Medical Center, Cincinnati, OH, 11Oklahoma Medical Research Foundation, Oklahoma City, OK, 12College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and identify individuals for prevention trials. Healthy blood relatives (FDRs) of lupus…
  • Abstract Number: 842 • 2013 ACR/ARHP Annual Meeting

    A Cytokine/Chemokine Multiplex Assay That Is Sensitive and Specific For Fibromyalgia Compared To Controls, Systemic Lupus Erythematosus, and Rheumatoid Arthritis

    Daniel J. Wallace1, Igor Gavin2, Oleksiy Karpenko2 and Bruce S. Gillis3, 1Cedars-Sinai Medical Center, Los Angeles, CA, 2University of Illinois College of Medicine at Chicago, Chicago, IL, 3Department of Pathology, University of Illinois College of Medicine at Chicago, Chicago, IL

    Background/Purpose:   Fibromyalgia (FM) is a chronic pain and fatigue syndrome that affects about 6 million adults in the United States.  The clinical diagnosis of…
  • Abstract Number: 2545 • 2013 ACR/ARHP Annual Meeting

    Active Systemic Lupus Erythematosus: Cytokines and Soluble Tumor Necrosis Factor Receptors Response To Moderate/Intense Exercise

    Luiz A. Perandini1, Diego Sales-de-Oliveira1, Suzana B.V. Mello2, Niels O Camara3, Fernanda R. Lima1, Eduardo F. Borba2, Eloisa Bonfa2, Ana Lucia Sá-Pinto1, Hamilton Roschel4 and Bruno Gualano5, 1University of Sao Paulo, Rheumatology Division, Sao Paulo, Brazil, 2University of Sao Paulo, Rheumatology Division, São Paulo, Brazil, 3Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil, 4Universidade de São Paulo, Faculdade de Educação Física e Esporte, São Paulo, Brazil, 5University of Sao Paulo, School of Physical Education and Sport, Sao Paulo, Brazil

    Background/Purpose: Systemic lupus erythematosus (SLE) is a rheumatic autoimmune condition characterized by altered lipoprotein profile, physical dysfunction and increased risk of cardiovascular disease. Exercise is,…
  • Abstract Number: 1685 • 2013 ACR/ARHP Annual Meeting

    Long-Term Use Of Tocilizumab For The Treatment Of Giant Cell Arteritis

    Sebastian Unizony1, John Stone2 and Brian Keroack3, 1Rheumatology, Massachusetts General Hospital, Boston, MA, 2Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3Rheumatology, Maine Medical Center, Tufts University Medical School, Maine, ME

    Background/Purpose: A sizeable percentage of giant cell arteritis (GCA) patients experience disease relapse upon glucocorticoid (GC) tapering, and a clearly effective GC-sparing alternative has not…
  • Abstract Number: 643 • 2013 ACR/ARHP Annual Meeting

    Potential Immunopathological Roles Of The Novel Anti-Inflammatory Cytokine Interleukin-35 In Patients With Systemic Lupus Erythematous

    Zhe Cai1, Chun-Kwok Wong2 and Lai Shan Tam3, 1The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong, 3Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong

    Background/Purpose: IL-35, a dimeric protein with two subunits, IL-12A (p35) and Epstein-Barr virus induced 3, is a novel IL-12 cytokine family regulatory T-cells (Treg)-specific immunosuppressive/anti-inflammatory…
  • Abstract Number: 2499 • 2013 ACR/ARHP Annual Meeting

    Analysis Of Inflammatory Markers Within Facet Joints Of Patients Within Ankylosing Spondylitis

    Uta Syrbe1, Janine Bleil2, Rene Maier3, Heiner Appel1 and Joachim Sieper4, 1Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, 2Charité, Berlin, Germany, 3Charite, Berlin, Germany, 4Charitè Campus Benjamin Franklin, Berlin, Germany

    Background/Purpose: Inflammation within sacroiliac joints and within the spine is a hallmark of ankylosing spondylitis (AS). Apart from nonsteroidal anti-rheumatic drug (NSAID) treatment, inhibition of…
  • Abstract Number: 1691 • 2013 ACR/ARHP Annual Meeting

    The STAT1 Signaling Pathway In Giant Cell Arteritis

    Bjorn Hartmann1, Joyce Liao2, Michael H. Weisman3, Kenneth J. Warrington4, Jorg J. Goronzy1 and Cornelia M. Weyand5, 1Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 2Byers Eye Institute at Stanford, Stanford University, Palo Alto, CA, 3Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 4Division of Rheumatology, Mayo Clinic, Rochester, MN, 5Medicine, Stanford University School of Medicine, Stanford, CA

    Background/Purpose: In giant cell arteritis (GCA), CD4 T cells, macrophages and multinucleated giant cells form granulomatous lesions in the walls of medium and large arteries.…
  • Abstract Number: 635 • 2013 ACR/ARHP Annual Meeting

    Multiple Altered Soluble Inflammatory Mediators Correlate With Disease Activity and Mark Impending Disease Flare In European-American Lupus Patients

    Melissa E. Munroe1, Jourdan R. Anderson2, Krista M. Bean3, Joan T. Merrill4, Joel M. Guthridge3, Virginia C. Roberts3, Linda F. Thompson5,6 and Judith A. James4,7, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5University of Oklahoma Health Sciences Center, Oklahoma City, OK, 6Immunobiology and Cancer, Oklahoma Medical Research Foundation, Oklahoma City, OK, 7College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose:  SLE is a waxing and waning disease characterized by immune dysregulation, major organ involvement, and disease flares. Identifying mechanistic mediators of altered disease activity…
  • Abstract Number: 2423 • 2013 ACR/ARHP Annual Meeting

    Mir-27b As Biomarker and Regulator Of IL-6R Pathway In Resistant Rheumatoid Arthritis Monocyte

    Marina Frleta1, Ashleigh-Ann Rainey2, Derek S. Gilchrist3, Lynn Crawford3, Derek Baxter3, Mariola Kurowska-Stolarska4 and Iain B. McInnes2, 1Institute of infection, immunity and inflammation, University of Glasgow, Glasgow, United Kingdom, 2Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 3Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 4Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Whereas molecular mechanisms mediating treatment responses to biologic DMARDS in Rheumatoid Arthritis (RA) are emerging, those pathways that subserve treatment resistance are poorly explored.…
  • Abstract Number: 1683 • 2013 ACR/ARHP Annual Meeting

    High Prevalence Of Metabolic Syndrome In Takayasu Arteritis: An Increased Cardiovascular Risk and Lower Adiponectin Serum Levels

    Thiago Silva1, Mauricio Levy-Neto2, Rosa M. R. Pereira3 and Eloisa Bonfa4, 1Rheumatology Division, University of São Paulo, São Paulo, Brazil, 2Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 3Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 4Rheumatology Division, Universidade de Sao Paulo, São Paulo, Brazil

    Background/Purpose: The prevalence of Metabolic Syndrome (MetS) tends to be high among rheumatic patients, and cardiovascular disease is the leading cause of death in these…
  • Abstract Number: 639 • 2013 ACR/ARHP Annual Meeting

    Examination Of The Cytokine Profile Of The Cerebrospinal Fluid In Neuropsychiatric Systemic Lupus Erythematosus

    Kunihiro Ichinose1, Takeshi Ushigusa2, Yoshikazu Nakashima3, Takahisa Suzuki3, Yoshiro Horai4, Shin-ya Kawashiri2, Naoki Iwamoto2, Mami Tamai3, Kazuhiko Arima4, Hideki Nakamura2, Tomoki Origuchi5 and Atsushi Kawakami4, 1Department of Immunology and Rheumatology, Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 4Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 5Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    Examination of the cytokine profile of the cerebrospinal fluid in neuropsychiatric systemic lupus erythematosusBackground/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious complication in systemic…
  • Abstract Number: 2392 • 2012 ACR/ARHP Annual Meeting

    Blood Vessel Instability and Oxidative Damage in Giant Cell Arteritis

    Danielle Molloy1, Jennifer McCormick2, Mary Connolly2, Muhammad Haroon3, Douglas J. Veale2, Conor Murphy4, Ursula Fearon2 and Eamonn S. Molloy1, 1Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, 2Rheumatology, Dublin Academic Medical Center, St. Vincent's University Hospital, Dublin, Ireland, 3Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 4Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland

    Background/Purpose: Giant cell arteritis (GCA) is the most common form of primary vasculitis. The pathogenesis is incompletely understood, but involves neoangiogenesis and inflammatory infiltration of…
  • Abstract Number: 1775 • 2012 ACR/ARHP Annual Meeting

    The Phosphoinositide 3-Kinase Pathway Regulates Fibroblast-Like Synoviocyte Invasion

    Beatrix Bartok1, Deepa Hammaker2 and Gary S. Firestein3, 1Rheumatology, UCSD, La Jolla, CA, 2MC 0656, Univ of California San Diego, La Jolla, CA, 3Div of Rheumatology, UCSD School of Medicine, La Jolla, CA

    Background/Purpose: Cartilage destruction mediated by invasive fibroblast-like synoviocytes (FLS) plays a central role in pathogenesis of RA. Increased cell migration and degradation of extracellular matrix…
  • Abstract Number: 1074 • 2012 ACR/ARHP Annual Meeting

    TLR2 Deletion Promotes Arthritis and Joint Destruction Through Reduction of IL-10

    Qi Quan Huang1, Renee E. Koessler1, Robert Birkett2, Harris R. Perlman3, Lianping Xing4 and Richard M. Pope5, 1Medicine/Rheumatology, Northwestern University, Chicago, IL, 2Division of Rheumatology, Department od Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Feinberg School of Medicine, Northwestern University, Chicago, IL, 4Pathology & Lab Medicine, University of Rochester, Rochester, NY, 5Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL

    Background/Purpose: TLR2 signaling pathway has been suggested as a potential therapeutic target in RA.  However, studies with mice deficient in TLR2 (TLR2-/-) and IL-1Ra suggest…
  • Abstract Number: 319 • 2012 ACR/ARHP Annual Meeting

    Gamma Interferon-Induced Protein-10 (IP-10) As a Potential Biomarker for Disease Activity in Pediatric Localized Scleroderma

    Katherine Kurzinski1, Carol A. Feghali-Bostwick2, Christina Kelsey1, Kelsey Magee3 and Kathryn S. Torok4, 1Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 2Medicine, University of Pittsburgh, Pittsburgh, PA, 3Pediatric Rheumatology, University of Pittsburgh, Pittsburgh, PA, 4Pediatric Rheumatology, Scleroderma Center of Pittsburgh, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA

    Background/Purpose: Pediatric localized scleroderma (LS) is an autoimmune disease affecting the skin and underlying tissue.  Cutaneous findings assist in categorizing the patients into active or…
  • « Previous Page
  • 1
  • …
  • 36
  • 37
  • 38
  • 39
  • 40
  • …
  • 42
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology